Roche’s Actemra Delayed By REMS, FDA Study Requirements

Roche expects to submit a complete response to FDA for the first-in-class IL-6 inhibitor for rheumatoid arthritis in the third quarter next year.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet